STANDARD BIOTOOLS INC. (LAB): Nasdaq/NYSE listing notice — Standard BioTools receives Nasdaq bid price deficiency notice; 180-day cure period through Oct 19, 2026

STANDARD BIOTOOLS INC.

Notice on April 20, 2026: common stock closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until October 19, 2026) to regain compliance by maintaining $1.00 closing bid for 10 consecutive days.
If eligible, company may transfer to Nasdaq Capital Market for an additional 180-day cure period, subject to fees and conditions.
Trading under ticker LAB continues uninterrupted; no effect on business operations or SEC reporting.
Company intends to cure, but no assurance of regaining compliance or extension.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

STANDARD BIOTOOLS INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 20, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) in

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-177290

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.